- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03908164
Optimising the Timing of Whooping Cough Immunisation in MUMs (OpTIMUM)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pertussis is a highly infectious respiratory illness caused by Bordetella pertussis, which characteristically causes paroxysms of coughing with an associated inspiratory 'whoop'. In young infants the clinical presentation can be atypical, is frequently associated with apnoeic episodes and can cause significant morbidity and mortality. Following the introduction of pertussis vaccination into routine infant schedules worldwide there was a significant reduction in the incidence of pertussis. However, recently in a number of countries, despite high vaccine coverage, there has been a resurgence of pertussis disease associated with an increase in infant deaths. Various strategies to control the increasing burden of infant pertussis disease have been considered including cocooning, a strategy in which close contacts of an infant are vaccinated, a neonatal dose of a pertussis containing vaccine, the addition of an adolescent dose to the schedule and vaccination in pregnancy. Of these, the latter has gained most support.
Vaccination in pregnancy is a strategy which relies on effective transport of antibody across the placenta, a process which depends on the antibody available, the gestation of the pregnancy and the health of the placenta. In the case of pertussis, the main aim is to prevent disease in babies (prior to the age of routine vaccination) as they have a higher mortality than any other age group from pertussis disease.
It is now clear that pertussis vaccination in pregnancy can reduce the burden of disease in young infants in the period prior to them being fully immunised, and can do so safely. However, it is not established whether there is an optimal time to vaccinate in pregnancy to ensure maximal protection of the infant. This is reflected in the different guidelines currently in place in different countries: in the UK vaccination is advised from 16 weeks gestation, in Canada from 26 weeks, in the USA from 27 weeks and in Australia from 28 weeks.
While some studies have suggested that vaccination later in pregnancy can achieve higher antibody concentrations in the newborn, others have found earlier vaccination provides improved immunity compared to later vaccination. The significance of this is that if earlier vaccination is shown to be equivalent, there are clear logistical benefits in allowing the widest possible time window in order to maximise the opportunities for pregnant women to be vaccinated and thereby improve vaccine coverage.
When the pertussis vaccination in pregnancy programmes were first implemented, vaccination was recommended in the third trimester (USA 27-36 weeks, UK 28-32 weeks). This decision was based on the hypothesis that vaccination would be most effective if it was timed to allow the peak in maternal antibody levels after vaccination to coincide with the time of most efficient placental transport.
There is a significant lack of agreement on optimal timing of pertussis vaccination in pregnancy due to conflicting data. This is the rationale for this randomised controlled trial.
In this study all participants will receive a pertussis containing vaccine licensed for use in pregnancy. In the UK currently the vaccine used is Boostrix-IPV® manufactured by GlaxoSmithKline. This vaccine contains pertussis toxin (PT) (8 micrograms), filamentous haemagglutinin (FHA) (8 micrograms) and pertactin (PRN) (2.5 micrograms) as well as diphtheria toxoid (not less than 2 international units), tetanus toxoids (not less than 20 international units) and inactivated polio virus types 1-3 (type 1 40 D-antigen unit, type 2 8 D-antigen unit, type 3 32 D-antigen unit). This vaccine will be given at the time period assigned by randomisation. All possible time periods included in the study are within that recommended in the UK as part of routine practice.
Participants will have blood sampling prior to vaccination, 14 days following vaccination and at the time of delivery. At delivery a cord blood sample will also be obtained and an infant sample taken from the infants of participating women at 28-42 days after completion of their primary immunisations.
There is a paucity of information about functional immunity of anti-PT antibody in serum and colostrum/breastmilk following vaccination in pregnancy. We will be investigating this in two exploratory sub-studies. The first of these (investigation of functional immunity of anti-PT antibody in serum) will be performed on samples being performed as part of the main study. For investigation of functional immunity of anti-PT antibody in colostrum and breastmilk we will ask participants at two participating institutions if they are willing to participate in a breastfeeding sub-study if they decide to breastfeed. For participants who take part in this sub-study a sample of colostrum will be obtained within 48 hours of delivery and a further breast milk sample at 14 days and 5 months following delivery.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
London
-
Tooting, London, United Kingdom, SW17 0QT
- St Georges University Hospital NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pregnant and not yet having received pertussis vaccination
- Willing and able to comply with study procedures and provide informed consent
- Documentation of a 20-week anomaly scan with no life limiting congenital anomalies identified
Exclusion Criteria:
- Age less than 16 years
- Confirmed or suspected pertussis in previous five years
- Known diagnosis of immune deficiency
- Receiving immunosuppressive medication within six months of enrolment in the study (this does not include inhaled or topical steroids)
- In the opinion of the investigator is unlikely to complete follow up
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Vaccination at <23+6 gestational weeks
Participants will receive a pertussis containing vaccine licensed for use in pregnancy before 23+6 gestational weeks (GW).
Although the time period for study group 1 is ≤23+6 no pertussis vaccine will be given in this study at less than 16 GW.
|
Participants will receive a pertussis containing vaccine licensed for use in pregnancy at one of three time periods.
|
EXPERIMENTAL: Vaccination at 24-27+6 gestational weeks
Participants will receive a pertussis containing vaccine licensed for use in pregnancy between 24 and 27+6 gestational weeks.
|
Participants will receive a pertussis containing vaccine licensed for use in pregnancy at one of three time periods.
|
EXPERIMENTAL: Vaccination at 28-31+6 gestational weeks
Participants will receive a pertussis containing vaccine licensed for use in pregnancy between 28 and 31+6 gestational weeks.
|
Participants will receive a pertussis containing vaccine licensed for use in pregnancy at one of three time periods.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pertussis specific antibody concentration in cord blood of term infants
Time Frame: Delivery of infant
|
Antibody concentrations against Pertussis Toxin (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) from cord blood of term infants.
This will be measured using ELISA.
|
Delivery of infant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pertussis specific antibody concentration in cord blood of preterm infants
Time Frame: Delivery of infant
|
Antibody concentrations against Pertussis Toxin (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) from cord blood of preterm infants.
This will be measured using ELISA.
|
Delivery of infant
|
Kinetics of antibody response to pertussis vaccination during pregnancy
Time Frame: Prior to vaccination, 14 days following vaccination, delivery
|
Antibody concentrations against Pertussis Toxin (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) in maternal blood prior to vaccination, 14 days following vaccination and at delivery.
This will be measured using ELISA.
|
Prior to vaccination, 14 days following vaccination, delivery
|
Placental transfer of antibody
Time Frame: Time of delivery
|
Antibody concentrations against Pertussis Toxin (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) in maternal and cord blood at time of delivery.
This will be measured using ELISA.
|
Time of delivery
|
Impact of repeated vaccination on antibody response in women who have received a pertussis vaccination in a previous pregnancy
Time Frame: Prior to vaccination, 14 days following vaccination and at delivery
|
Antibody concentrations against Pertussis Toxin (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) in maternal blood prior to vaccination, 14 days following vaccination and at delivery.
This will be measured using ELISA.
|
Prior to vaccination, 14 days following vaccination and at delivery
|
Antibody concentration in infants following primary immunisation schedule
Time Frame: 28-42 days following completion of primary immunisations
|
Antibody concentrations against Pertussis Toxin (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) from the infant following primary immunisations.
This will be measured using ELISA.
|
28-42 days following completion of primary immunisations
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional assays on serum
Time Frame: Samples collected following vaccination, from the cord blood at delivery and in the infants following primary vaccination.
|
Serum bactericidal assays will be performed.
The bactericidal titre is the last serum dilution where ≥50% killing is observed compared to complement only control.
Serum bactericidal assays will be performed and the bactericidal titre will be compared according to the time of vaccination.
|
Samples collected following vaccination, from the cord blood at delivery and in the infants following primary vaccination.
|
Collaborators and Investigators
Investigators
- Study Chair: Paul Heath, St George's, University of London
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018.0297
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pertussis
-
National Institute of Allergy and Infectious Diseases...CompletedPertussis | Pertussis ImmunisationUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis (Whooping Cough)France
-
Institut PasteurHopital Universitaire Robert-Debre; Hospices Civils de Lyon; Centre Hospitalier... and other collaboratorsNot yet recruitingBordetella Pertussis, Whooping CoughFrance
-
ILiAD BiotechnologiesActive, not recruitingBordetella Pertussis, Whooping CoughUnited Kingdom, Australia, Costa Rica
-
University of TurkuGlaxoSmithKline; Sanofi Pasteur, a Sanofi CompanyCompleted
-
Institut PasteurAgence de Médecine Préventive, France; Institut Pasteur de Madagascar; Institut...CompletedBordetella Pertussis, Whooping CoughCambodia, Madagascar, Togo
-
Institut PasteurSanofi Pasteur, a Sanofi Company; Institut Pasteur of Cote d'IvoireCompletedBordetella Pertussis, Whooping CoughCôte D'Ivoire
-
GlaxoSmithKlineCompletedPertussis | Pertussis VaccinesHungary
-
University of SouthamptonRecruitingPertussis/Whooping CoughUnited Kingdom
-
Association Clinique Thérapeutique Infantile du...Sanofi; GlaxoSmithKline; Merck Sharp & Dohme LLCRecruitingChildren, Only | Ambulatory | Pertussis/Whooping CoughFrance
Clinical Trials on Pertussis containing vaccine
-
Centre Hospitalier Universitaire Saint PierreUniversité Libre de BruxellesNot yet recruitingPertussis | Maternal-Fetal Relations | Vaccination; Infection | ImmunoglobulinsBelgium
-
Universiteit AntwerpenChulalongkorn University; Thrasher Research Fund; Institut Pasteur de LilleCompleted
-
St George's, University of LondonMax Planck Institute for Infection Biology; Innovative Medicine InitiativeCompletedPregnancy Related | VaccinationUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...Istituto Superiore di SanitàCompleted
-
Universiteit AntwerpenUniversity Hospital, Antwerp; Research Foundation Flanders; Université Libre...Active, not recruiting
-
Public Health EnglandInstitute of Child Health; St George's, University of LondonCompletedResponses to Infant ImmunisationsUnited Kingdom
-
Public Health EnglandCompletedPertussis | Meningitis | Immunization | Preventive Immunization; MeningitisUnited Kingdom
-
GlaxoSmithKlineCompletedTetanus | Diphtheria | Acellular Pertussis | Haemophilus Influenzae Type bChina
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Whooping Cough | Tetanus | DiphtheriaUnited States
-
Central Hospital, Nancy, FranceUnknownDiphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates (VacciPrema)Hib Immunisation in Very Preterm-born Infants | Pertussis Immunisation in Very Preterm-born InfantsFrance